Despite the success of renin-angiotensin system (RAS) blockade by angiotensin-converting
enzyme (ACE) inhibitors and angiotensin II type 1 receptor (AT 1 R) blockers, current …

Cardiovascular disease (CVD) is the main cause of death globally and responsible for the
second highest number of deaths in Canada. Medical advancements in the treatment of …

Introduction The significant morbidity and mortality in patients with heart failure (HF), notably
in the most advanced forms of the disease, justify the need for novel therapeutic options. In …

Despite the progressive improvements in diagnosis and therapy during the first 20 years of
this century, the morbidity and mortality of patients with heart failure (HF) remain high …

Background LCZ696, an angiotensin receptor–neprilysin inhibitor (ARNi), is reported to play
a cardioprotective role after acute myocardial infarction (AMI). Angiotensin-converting …

Heart failure caused by cardiac fibrosis has become a major challenge of public health
worldwide. Cardiomyocyte programmed cell death (PCD) and activation of fibroblasts are …

Arterial hypertension is the most prevalent chronic disease in the adult population of
developed countries and it constitutes a significant risk factor in the development of …

Background: Sacubitril/valsartan (LCZ696) has progressed to be one of the most promising
medication since its approval for chronic heart failure with reduced ejection fraction. Recent …

From a pathogenetic point of view, heart failure (HF) is characterized by the activation of
several neurohumoral pathways with a role in maintaining the cardiac output and the …

This study evaluated the effect of sacubtril/valsartan on cardiac remodeling, molecular and
cellular adaptations in experimental (rat) model of hypertension-induced hypertrophic …